Ashfield, part of UDG Healthcare plc

ashfieldhealthcare.com

Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across two broad areas of activity: commercial and clinical services, and communications services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies in 22 countries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

ACORDA THERAPEUTICS ENTERS INTO LICENSE AGREEMENT WITH ASIERIS PHARMACEUTICALS

Asieris | August 30, 2022

news image

Acorda Therapeutics, Inc. announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agreement, Acorda will receive an upfront payment of $500,000, and up to an additional $7 million based on the achievement of regulatory milestones. Acorda will also receive a royalty on future net sales. Nepicastat is a small molecule drug and the license...

Read More

Business Insights

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals | August 23, 2021

news image

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More

Pharma Tech

HOUSE RX TO LAUNCH SPECIALTY DRUG DISPENSING INSIDE RHEUMATOLOGY CLINICS BY PARTNERING WITH THREE LEADING PRACTICES

House Rx | August 04, 2022

news image

House Rx, the platform for medically integrated dispensing of specialty medications, announced it has partnered with three new rheumatology clinics to integrate in-house specialty drug dispensing – also known as medically integrated dispensing (MID) – into the clinics' operations. The three practices are: Arizona Arthritis & Rheumatology Associates (AARA), Arthritis & Osteoporosis Consultants of the Carolinas (AOCC), and Arthritis Associates of Tennessee and represent an ...

Read More

U.S. STATES BUILD STOCKPILES OF MALARIA DRUG TOUTED BY TRUMP

Abcnews | April 26, 2020

news image

State and local governments across the United States have obtained about 30 million doses of a malaria drug touted by President Trump to treat patients with the coronavirus, despite warnings from doctors that more research is needed. At least 22 states and Washington, D.C., secured shipments of the drug, hydroxychloroquine, according to information compiled from state and federal officials by The Associated Press. Sixteen of those states were won by Trump in 2016, although five of them, includin...

Read More
news image

Pharmacy Market

ACORDA THERAPEUTICS ENTERS INTO LICENSE AGREEMENT WITH ASIERIS PHARMACEUTICALS

Asieris | August 30, 2022

Acorda Therapeutics, Inc. announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agreement, Acorda will receive an upfront payment of $500,000, and up to an additional $7 million based on the achievement of regulatory milestones. Acorda will also receive a royalty on future net sales. Nepicastat is a small molecule drug and the license...

Read More
news image

Business Insights

INDEX PHARMACEUTICALS STRENGTHENS THE CLINICAL DEVELOPMENT ORGANIZATION IN PREPARATION OF THE START OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD

InDex Pharmaceuticals | August 23, 2021

InDex Pharmaceuticals Holding AB today announced that two new employees have been appointed in the clinical development organisation in preparation of the start of the phase III study CONCLUDE with cobitolimod. Anders Bröijersén is joining InDex as Senior Medical Director Clinical Operations and Johan Levin as Project Manager Clinical Operations. Anders Bröijersén is a medical doctor and PhD with 15 years of experience in Clinical Development...

Read More
news image

Pharma Tech

HOUSE RX TO LAUNCH SPECIALTY DRUG DISPENSING INSIDE RHEUMATOLOGY CLINICS BY PARTNERING WITH THREE LEADING PRACTICES

House Rx | August 04, 2022

House Rx, the platform for medically integrated dispensing of specialty medications, announced it has partnered with three new rheumatology clinics to integrate in-house specialty drug dispensing – also known as medically integrated dispensing (MID) – into the clinics' operations. The three practices are: Arizona Arthritis & Rheumatology Associates (AARA), Arthritis & Osteoporosis Consultants of the Carolinas (AOCC), and Arthritis Associates of Tennessee and represent an ...

Read More
news image

U.S. STATES BUILD STOCKPILES OF MALARIA DRUG TOUTED BY TRUMP

Abcnews | April 26, 2020

State and local governments across the United States have obtained about 30 million doses of a malaria drug touted by President Trump to treat patients with the coronavirus, despite warnings from doctors that more research is needed. At least 22 states and Washington, D.C., secured shipments of the drug, hydroxychloroquine, according to information compiled from state and federal officials by The Associated Press. Sixteen of those states were won by Trump in 2016, although five of them, includin...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us